Desenvolvimento de porta-enxertos de umbuzeiro em resposta à adubação com nitrogênio e fósforo ‘Umbuzeiro’ rootstocks development as a answer for fertilization with nitrogen and phosphorous

A adubação, notadamente com nitrogênio e fósforo, é fundamental no estádio de desenvolvimento inicial de mudas de frutíferas. Porém, existem poucas informações científicas com respeito do umbuzeiro. Assim, objetivou-se avaliar o efeito de doses de nitrogênio e fósforo no desenvolvimento de porta-enxertos de umbuzeiro (Spondias tuberosa Arr. Câm.). O experimento foi conduzido sob telado, na Universidade Federal de Sergipe, em um delineamento em blocos ao acaso, em esquema fatorial 4 x 4, sendo quatro níveis de nitrogênio e quatro de fósforo (0, 50, 100 e 150kg ha-1 de N e P2O5, respectivamente na forma de uréia e superfosfato simples, em quatro repetições. O maior ganho em altura (12,52cm) foi obtido com as doses de 97,58kg ha-1 de N, enquanto o maior incremento no diâmetro do colo (2,18mm) foi obtido com as doses de 150kg ha-1 de N e 150kg ha-1 de P2O5. O maior número de folhas foi observado na presença de 126,03kg ha-1 de N e 150kg ha-1 de P2O5. A maior produção de massa seca da parte aérea total foi constatada na dose de 98,71kg ha-1 de N e 150kg ha-1 de P2O5. A área foliar cresceu linearmente para ambos fatores As adubações estudadas contribuem de forma positiva para a formação de mudas de umbuzeiro, podendo antecipar a formação de porta-enxertos para algumas fruteiras do gênero Spondias. Doses de fósforo a partir de 150kg ha-1 não são recomendadas quando se pretende produzir picles, a partir do xilopódio do umbuzeiro.<br>The fertilization, notable with nitrogen and phosphorous, is fundamental on initial development stadium on fruits nursery trees. However, there is little scientific information about ‘umbuzeiro’. This work had as objective to evaluate the effect of nitrogen and phosphorous’ doses on ‘umbuzeiro’ rootstocks (Spondias tuberosa Arr. Câm.). The experiment was carried out under nursery at ‘Universidade Federal de Sergipe’ being used experimental design of randomized blocks in factorial 4X4 with four levels of nitrogen and four levels of phosphorous (0, 50, 100 and 150kg ha-1 of N and P2O5) respectively under urea form and simple superphosphate, with four replications. The higher rootstock (12.52cm) was obtained with doses of 97.58kg ha-1 of N, the higher stem diameter (2.18mm) was obtained with doses of 150kg ha-1 of N and 150kg ha-1 of P2O5. The major number of leaves was observed on presence of 126.03kg ha-1 of N and 150kg ha-1 of P2O5. The major dry matter production of total aerial plant was verified with a dose of 98.71kg ha-1 of N and 150kg ha-1 of P2O5. The leaf area presented a linear grown for both factors. The nitrogen and phosphorous fertilization contribute as positive performance on ‘umbuzeiro’ doing the rootstocks development anticipated for some fruit trees of the Spondias genus. Phosphorous’ doses from 150kg ha-1 were not recommended for pickles production using ‘umbuzeiro’ xylopodium

Urticaria exacerbations and adverse reactions in patients with chronic urticaria receiving COVID-19 vaccination : results of the UCARE COVAC-CU study

Background: Concern about disease exacerbations and fear of reactions after coronavirus disease 2019 (COVID-19) vaccinations are common in chronic urticaria (CU) patients and may lead to vaccine hesitancy. Objective: We assessed the frequency and risk factors of CU exacerbation and adverse reactions in CU patients after COVID-19 vaccination. Methods: COVAC-CU is an international multicenter study of Urticaria Centers of Reference and Excellence (UCAREs) that retrospectively evaluated the effects of COVID-19 vaccination in CU patients aged ≥18 years and vaccinated with ≥1 dose of any COVID-19 vaccine. We evaluated CU exacerbations and severe allergic reactions as well as other adverse events associated with COVID-19 vaccinations and their association with various CU parameters. Results: Across 2769 COVID-19–vaccinated CU patients, most (90%) received at least 2 COVID-19 vaccine doses, and most patients received CU treatment and had well-controlled disease. The rate of COVID-19 vaccination–induced CU exacerbation was 9%. Of 223 patients with CU exacerbation after the first dose, 53.4% experienced recurrence of CU exacerbation after the second dose. CU exacerbation most often started <48 hours after vaccination (59.2%), lasted for a few weeks or less (70%), and was treated mainly with antihistamines (70.3%). Factors that increased the risk for COVID-19 vaccination–induced CU exacerbation included female sex, disease duration shorter than 24 months, having chronic spontaneous versus inducible urticaria, receipt of adenovirus viral vector vaccine, having nonsteroidal anti-inflammatory drug/aspirin intolerance, and having concerns about getting vaccinated; receiving omalizumab treatment and Latino/Hispanic ethnicity lowered the risk. First-dose vaccine–related adverse effects, most commonly local reactions, fever, fatigue, and muscle pain, were reported by 43.5% of CU patients. Seven patients reported severe allergic reactions. Conclusions: COVID-19 vaccination leads to disease exacerbation in only a small number of CU patients and is generally well tolerated